Have questions about the economic measures put in place to support businesses affected by the coronavirus (COVID-19)? Visit the Québec.ca.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. website.

Ouvrir ou fermer le menu de navigation

La page est en cours de chargement...  

Bannière Excellence Québec

Québec is collaboration

World-class partners open to collaboration

Québec is fertile ground for collaborative health research. It has:

  • Over 20 public research centres
  • 18 research networks
  • Numerous multidisciplinary health research groups
  • Numerous health research organizations

Five research centres and university hospitals open to collaboration

University of Montreal Hospital Center - Research center

Six research focus areas

  • Cancer
  • Cardiometabolic disease
  • Tissue injury, infection, immunity and inflammation
  • Imaging and engineering
  • Neuroscience
  • Health innovation and evaluation hub

Website: University of Montreal Hospital Center - Research center.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.

Research Institute of the McGill University Health Centre (RI-MUHC)

Eleven research focus areas

  • Cancer
  • Endocrinology, diabetes, nutrition and kidney disease
  • Medical genetics and genomics
  • Infection and immunity
  • Cardiovascular disease and intensive care
  • Mental illness and addiction
  • Neuroscience
  • Evaluative health research
  • Human reproduction and development
  • Respiratory health
  • Musculoskeletal disorders

Website: Research Institute of the McGill University Health Centre.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.

Sainte-Justine University Hospital - Research center

Five child-oriented research themes

  • Child and child brain development
  • Musculoskeletal disease and rehabilitation
  • Viral and immunological disease and cancer
  • Fetomaternal and neonatal pathology
  • Metabolic health and complex diseases

Website: Sainte-Justine University Hospital - Research center.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.

Centre de recherche clinique of the Centre hospitalier universitaire de Sherbrooke

Six research themes

  • Cancer:
    • Biology
    • Prognosis
    • Diagnosis
  • Diabetes, obesity and cardiovascular complications
  • Medical imaging
  • Inflammation and pain
  • Mother–child
  • Health:
    • Populations
    • Organization
    • Practices

Website: Centre de recherche clinique of the Centre hospitalier universitaire de Sherbrooke.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.

Centre hospitalier universitaire de Québec - Research center

Seven research themes

  • Endocrinology and nephrology
  • Infectious and immunological disease
  • Regenerative medicine
  • Neuroscience
  • Oncology
  • Reproduction and mother and child health
  • Population health and best health practices

Website: Centre hospitalier universitaire de Québec - Research center.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.

Organizations open to collaboration

Commercialization

Centre for commercialization of cancer immunotherapy (C3I)

Created in 2015, C3I.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. accelerates patient access to innovative cancer immunotherapies, providing an integrated structure for their development, application and commercialization.

It provides cutting-edge biomarker and diagnostic tests, best practice standards in manufacturing, early access to clinical trials and regulatory support to bring quick, effective and affordable care to Canadians and people around the world.

C3I solidifies Québec’s position as a leader in cancer immunotherapy.

It helps health professionals and patients get early access to promising therapies at the developmental stage.

Key partnerships between C3I and pharmaceutical companies have paved the way for the first clinical trials in Québec using cutting-edge technology based on cellular therapy.

Centre d’excellence en thérapie cellulaire* (CETC) is one of the units C3I represents. CETC is a fully operational state-of-the-art laboratory that specializes in developing cellular therapy in accordance with current best manufacturing practices (BMP), in particular cancer immunotherapy treatments. Located at Hôpital Maisonneuve-Rosemont, CETC facilities are validated and meet the requirements of Canadian regulators, the EMA and the FDA.

*In French only.

Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

Established in 2008, IRICoR.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. is an integrated not-for-profit drug discovery and commercialization centre affiliated with the IRIC. Its mission is ensure the development of the most promising projects of the IRIC, other Université de Montréal units and various organizations in order to promote financial and strategic partnerships to accelerate the commercialization of new therapies in cancer, immunology and related fields.

So far, IRICoR has:

  • Entered into five major partnerships with biopharmaceutical companies, such as Bristol-Myers Squibb, Pfizer, Merck and Pharmascience
  • Initiated clinical trials after validating targets and identifying candidate molecules
  • Created two spin-off companies (ExCellThera and Domain Therapeutics North America)
  • Developed 24 patent families

The institute has generated $6 in profits for each dollar in initial funding.

Clinical research

Montreal Health Innovations Coordinating Centre (MHICC) and Montreal Heart Institute (MHI)

MHICC.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité., a division of the MHI.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité., is a university clinical research organization. It provides a full range of services and serves the university community, pharmaceutical and biotechnological industries and medical devices sector in the following areas:

  • Cardiology
  • Neurology
  • Oncology
  • Dermatology
  • Endocrinology
  • Pharmacogenomics

Affiliated with Université de Montréal, the MHI is highly specialized in cardiology. Averaging $705,500 in investment per researcher, the hospital leads Canada in terms of research intensity.

Consortium de recherche en oncologie clinique du Québec (Q-CROC)

Q-CROC.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. is a provincial clinical cancer research interface that serves as a bridge between:

  • Industry stakeholders
  • Government stakeholders
  • Healthcare stakeholders
  • Research stakeholders

The Consortium leverages its knowledge to make clinical research in Québec more competitive and attract more studies to the province.

It also contributes to the growth of a research niche aimed at discovering and validating biomarkers that will allow us to predict responses and resistance to treatments.

Pre-competitive research

CQDM

CQDM.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. is a pre-competitive drug discovery research consortium set up to fund the development of breakthrough tools and technologies enhancing the productivity of biopharmaceutical R&D. CQDM is jointly funded by the Government of Québec and nine major pharmaceutical companies:

  • Pfizer
  • Merck
  • AstraZeneca
  • Eli Lilly
  • Boehringer Ingelheim
  • GSK
  • Novartis
  • Janssen
  • Sanofi

Medical technology

TransMedTech Institute

The TransMedTech Institute.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. works to develop medical diagnosis and treatment technologies, especially in the fields of orthopedics, cardiovascular disease and oncology. It comprises Polytechnique Montréal and a number of other university hospital research centres.

The institute features an open innovation ecosystem driven by engineers, biomedical scientists, clinicians, patients, students, healthcare workers and policy-makers.

The TransMedTech Institute’s R&D activities are directly focused on the needs of patients, healthcare professionals and the healthcare system.

Data valorization

Institute for Data Valorization (IVADO)

Led by Campus Montréal, a joint initiative by Université de Montréal, HEC Montréal and Polytechnique Montréal, IVADO.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité.’s goal is to create synergy between its three fields of expertise:

  • data analytics,
  • operational research,
  • artificial intelligence.

With over 900 affiliated scientists, IVADO provides a link between academic expertise and the needs of businesses, from startups to multinationals. 

Research centres and organizations

Institute for Research in Immunology and Cancer (IRIC)

IRIC.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité., Université de Montréal’s cancer research centre, has adopted a model that’s unique in Canada. Its mission is to study cancer mechanisms and to accelerate the discovery of more effective cancer therapies.

IRIC boasts a team of 500 and the most impressive biomedical research technology park in Canada, which is also used by other research centres.

McGill University and Génome Québec Innovation Centre

The McGill University and Génome Québec Innovation Centre.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité. has over 80 employees. It’s the main genomics platform in Canada.

By supporting more than 80 projects and 900 researchers and managing the Innovation Centre’s activities, Génome Québec is accelerating the arrival of new applications in strategic sectors such as:

  • Personalized health
  • Forestry
  • Environment
  • Agro-food

Over the years, the Innovation Centre has built extensive expertise in the area of complex genetic disorders. A third of its activities are currently aimed at clients outside Québec.

NEOMED R&D, the NEOMED Institute and the Biologics and Vaccine Centre of Excellence

In November 2012, the Government of Québec teamed up with private partners AstraZeneca and Pfizer to launch NEOMED and the NEOMED Institute.  Ce lien mène à un site qui n'est peut-être pas soumis au standard gouvernemental sur l'accessibilité..

Since 2016, Janssen and Purdue Pharma have also joined the initiative. Furthermore, GSK will be investing $47 million in the Biologics and Vaccine Centre of Excellence. Created in 2015, this centre is unique in Canada.
NEOMED is a not-for-profit research consortium that operates as a conventional biotech company. NEOMED oversees its own drug development projects.

The NEOMED Institute has operated out of AstraZeneca’s former facilities in Technoparc Montreal since 2012, and also out of the former GSK Vaccines research centre in Laval—where the Biologics and Vaccine Centre of Excellence was established—since February 2015.

These two state-of-the-art R&D facilities serve as open-access hubs bringing together various companies and independent organizations with a view to fostering collaboration, innovation and creativity.

In less than five years, 29 companies and organizations have set up shop at the two facilities, which now have 340 employees.

Oncopole

Launched in February 2017, Oncopole is a research, development and investment hub aimed at accelerating the fight against cancer.

It gathers various partners around a capacity-building project. Oncopole is a one-of-a-kind co-creative partnership with an inclusive ideation and implementation process connected to the scientific community.

Fonds de recherche du Québec-Santé (FRQS) and Merck jointly announced this initiative, and the latter will be investing $15 million in it by 2020.

FRQS and Merck hope this initial funding will encourage other partners to join Oncopole and transform this project into a major oncology innovation hub.

Last update: April 30 2020

Ministère de l'Économie et de l'Innovation

© Gouvernement du Québec, 2020

Suivez-nous

  • LinkedIn
  • Youtube
  • Instagram